Fidelity Investments
CAPR icon

Fidelity Investments’s Capricor Therapeutics CAPR Stock Holding History

Fidelity Investments’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4M Buy
1,137,730
+365,081
+47% +$11.1M ﹤0.01% 1755
2026
Q1 		$23.5M Sell
772,649
-149,985
-16% -$4M ﹤0.01% 1722
2025
Q4 		$26.6M Buy
922,634
+898,944
+3,795% +$11.7M ﹤0.01% 1673
2025
Q3 		$171K Sell
23,690
-500
-2% -$3.68K ﹤0.01% 3425
2025
Q2 		$240K Sell
24,190
-566
-2% -$5.98K ﹤0.01% 3241
2025
Q1 		$235K Buy
24,756
+949
+4% +$13.2K ﹤0.01% 3184
2024
Q4 		$329K Sell
23,807
-537
-2% -$9.41K ﹤0.01% 3071
2024
Q3 		$370K Buy
+24,344
New +$120K ﹤0.01% 2982
2024
Q2 		– Sell
-1
Closed -$7 – 5394
2024
Q1 		$7 Buy
+1
New +$5 ﹤0.01% 5286
2021
Q4 		– Sell
-40
Closed – – 4374
2021
Q3 		$0 Hold
40
– – ﹤0.01% 4391
2021
Q2 		$0 Sell
40
-185
-82% -$784 ﹤0.01% 4284
2021
Q1 		$1K Buy
+225
New +$1.3K ﹤0.01% 3805

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fidelity Investments's CAPR Position: Q2 2026 in Review

Fidelity Investments increased its Capricor Therapeutics (CAPR) stake by 47% in Q2 2026, buying an estimated $11.1M and bringing the position to 1,137,730 shares worth $27.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Fidelity Investments first reported a position in CAPR in Q1 2021 and has held it in 12 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Fidelity Investments held 1,137,730 shares of Capricor Therapeutics worth $27.4M as of Q2 2026.
  • Fidelity Investments bought 365,081 Capricor Therapeutics shares in Q2 2026, an estimated $11.1M.
  • Capricor Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1755 holding.
  • Fidelity Investments first reported a position in Capricor Therapeutics in Q1 2021 and has held it in 12 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.